Departamento de Bioquímica, Biología Molecular III e Inmunología, University of Granada, Granada, Spain.
Programa de doctorado en Biomedicina, University of Granada, Granada, Spain.
APMIS. 2022 May;130(5):261-269. doi: 10.1111/apm.13215. Epub 2022 Mar 3.
The new vaccines against SARS-CoV-2 have raised a lot of expectations about their ability to induce immunity and the duration of this. This is the case of mRNA vaccines such as Moderna's mRNA-1273. Therefore, it is necessary to study the humoral and cellular immunity generated by these vaccines. Our objectives are determining what is the normal response of antibody production, and what is the level of protective antibodies and monitoring patients in case of subsequent infection with COVID-19. We present the first results of a longitudinal study of the humoral response in 601 health workers vaccinated with Moderna. The results show a humoral immunity at 90 days after the second dose of 100%, with a strong decrease between the levels of circulating anti-S IgG antibodies between days 30 and 90 post-vaccination. Observing a steeper decline in those who had higher titles at the beginning. In addition, we present a cellular response of 86% at three months after the second dose, which is related to low humoral response.
新型的 SARS-CoV-2 疫苗引发了人们对其诱导免疫能力和持续时间的高度期待。mRNA 疫苗如 Moderna 的 mRNA-1273 就是一个典型的例子。因此，有必要研究这些疫苗产生的体液和细胞免疫。我们的目标是确定抗体产生的正常反应是什么，以及保护性抗体的水平，并在 COVID-19 后续感染时对患者进行监测。我们介绍了一项对 601 名接种 Moderna 疫苗的卫生工作者进行的体液免疫纵向研究的初步结果。结果表明，在第二剂疫苗接种后 90 天，体液免疫达到 100%，在接种后 30 至 90 天之间，循环抗-S IgG 抗体水平呈强下降趋势。在开始时滴度较高的人群中，这种下降更为陡峭。此外，我们还展示了第二剂疫苗接种三个月后的 86%的细胞免疫反应，这与低体液反应有关。
